Medical Oncology

Would non-gastric GISTs, high mitotic rate, large size, and young age of patient affect your decision? Especially knowing that TKIs suppress cell grow...

1 Answer available

How do you approach a patient with newly diagnosed high-grade osteosarcoma who received maximum cumulative dose of doxorubicin for a soft tissue sarcoma 10 years earlier?

3 Answers available

How do you integrate surgery in treatment of recurrent tenosynovial giant cell tumors (TGCT) when using Pexidartinib?

1 Answer available

Do you ever extend adjuvant imatinib for patients with high-risk, localized GIST beyond 3 years?

If so, which patients would you extend treatment?

2 Answers available

How would you manage primary breast osteosarcoma?

2 Answers available

How would you treat a patient with a locally recurrent myxofibrosarcoma, FNCLCC grade 2, that has recurred after multiple resections and radiotherapy?

1 Answer available

What is the role of local control +/- whole lung irradiation in a patient with relapsed/refractory Ewing sarcoma to the hilum plus multiple lung nodules?

Patient initially achieved CR with VAC-IE with resolution of presumed lung mets and 100% necrosis in LLE primary tumor on BKA. Then was NED again afte...

2 Answers available

Outside of a clinical trial, what is your preferred first-line therapy for a fit patient with de novo metastatic spindle cell sarcoma?

What role, if any, does molecular testing play in diagnosis and management in the absence of available clinical trials?

1 Answer available

Would you give doxorubicin and cisplatin for localized chondroblastic osteosarcoma in a patient with prior childhood anthracycline exposure and resultant cardiomyopathy with EF 50%?

3 Answers available

How would you approach an adult patient >50 years old with an intermediate risk extremity T2N0 fusion neg rhabdomyosarcoma who is progressing on neoadjuvant chemotherapy with VAC?

How would you add radiation in your treatment paradigm? No clinical trials available due to age.

2 Answers available

What is the optimal frequency and duration of post-operative radiological surveillance following resection of a solitary fibrous tumor?

1 Answer available

What third and fourth line options do you consider for patients with pleomorphic sarcoma and a good performance status who have progressed on standard anthracycline and gemcitabine/docetaxel?

1 Answer available

How would you approach the adjuvant treatment of a stage IVA adenosarcoma of the ovary?

Would your systemic therapy choice be more similar to treatment of ovarian carcinoma or soft tissue sarcoma?

1 Answer available

Would you give chemotherapy to a fit patient with myxoid liposarcoma of the knee that is resectable with adverse functional outcomes who will be undergoing neoadjuvant radiation and resection?

If yes, would you offer neoadjuvant or adjuvant, concurrent or sequential?

1 Answer available

How would you approach a sarcoma that was initially diagnosed as UPS of the distal femur with groin lymph node spread, resected, and found to have an EWSR1-FLI1 fusion diagnostic of Ewing's on NGS?

1 Answer available

What is your treatment approach for a pediatric patient with uterine embryonal rhabdomyosarcoma found after removal of a prolapsing uterine mass, with no evidence of distant metastasis on imaging?

1 Answer available

How would you approach adjuvant therapy for resected spindle cell rhabdosarcoma of the tongue?

Margins are negative (closest 4mm), grade 2, 3 of 23 lymph nodes positive with no extranodal extension. What is your preferred chemotherapy approach a...

1 Answer available

How would you manage an adult patient status post subtotal resection of spinal osteoblastoma?

The patient presented with spinal cord compression, had subtotal resection and instrumentation with metallic hardware. Main concern is that post op su...

1 Answer available

How would you approach the adjuvant management of thoracic SMARCA4-deficient undifferentiated tumor of the lung following lobectomy?

4 cm with negative LN

1 Answer available

What treatment would you recommend for a patient with recurrent oligometastatic abdominal leiomyosarcoma, with two liver lesions?

No evidence of distant disease elsewhere. Surgical resection is not possible. Would you recommend metastasis direct therapy to the liver (i.e. SBRT or...

2 Answers available

Is there any role for neoadjuvant chemotherapy in renal leiomyosarcoma?

Very rare tumor with sparse literature

1 Answer available

What is your preferred first line treatment for metastatic follicular dendritic cell sarcoma?

Would you use gem/docetaxel, anthracycline-based regimens or targeted therapies?

1 Answer available

How do you treat metastatic, wild-type GIST?

1 Answer available

How would you manage a patient with epithelioid hemangioendothelioma?

1 Answer available

Would you consider adjuvant chemotherapy in the management of retroperitoneal leiomyoscarcoma who did not respond to neoadjuvant doxorubicin/dacarbazine?

And if so which?

2 Answers available

What, if any, adjuvant therapy would you offer a high risk (based on size, location, mitotic rate) GIST patient who is wild type or PDGFRA D842V mutated?

1 Answer available

How would you treat a locally-recurrent extraosseous (pulmonary) Ewing sarcoma?

Ewing sarcoma of the right lung, status post bi-lobectomy and adjuvant VDC/IE, with recurrence 6 years in the right lung only. He has reached a cumula...

1 Answer available

Would you give liposomal doxorubicin to a patient with recurrent left thigh atypical spindle cell lipomatous tumor, low to intermediate grade, that is not a surgical or radiation candidate?

Pathology did not meet criteria for a well-differentiated nor dedifferentiated liposarcoma, nor a spindle cell sarcoma.

1 Answer available

How do you approach treatment of recurrent histiocytic sarcoma in a young, healthy patient after surgical resection?

1 Answer available

When should adjuvant chemotherapy be offered to patients with soft tissue sarcoma of the extremity?

With conflicting data from the EORTC RCT and the Sarcoma meta-analysis collaboration, what factors determine when you would offer adjuvant chemotherap...

2 Answers available

When chemotherapy is indicated in early stage soft tissue sarcoma, would you prefer to use AD or AI?

AD: doxorubicin + dacarbazine AI: doxorubicin + ifosfamide

1 Answer available

How do you incorporate denosumab into the surgical management of giant cell tumor of bone?

Does the degree of resectability affect your management?

2 Answers available

What treatment would you recommend for a patient with multi-focal angiosarcoma involving the gastrointestinal tract?

How would you modify therapy for a younger, fit patient versus an older, frail patient? Lesions in stomach, small intestine, colon resulting in bleed...

3 Answers available

What is the role of adjuvant chemotherapy in a desmoid tumor after R2 resection?

1 Answer available

Would differentiating between embryonal vs alveolar rhabdomyosarcoma of the nasal cavity change your neoadjuvant chemotherapy regimen or make you consider neoadjuvant radiation in a locally advanced pleomorphic RMS?

40 yo adult patient with a~6cm mass with concern for skull base bony involvement (group III and stage III, no nodal involvement )

1 Answer available

Is there any outpatient protocol for cisplatin/doxorubicin neoadjuvant chemotherapy for osteosarcoma?

1 Answer available

What is the optimal duration for denosumab use in the setting of recurrent, un-resectable giant cell tumor?

Received optimal pre-op denosumab; only option is now amputation

2 Answers available

How would you approach unresectable cutaneous angiosarcoma of the scalp?

What would be your radiation volumes/dose and choice of chemotherapy?

3 Answers available

What adjuvant therapy would you recommend for a T3N0, grade 3, undifferentiated sarcoma of the mandible with positive margins that is not amenable to re-resection?

Would you offer adjuvant RT or chemotherapy? If so, what chemotherapy would you prefer?

2 Answers available

What is your preferred first-line therapy for metastatic extraskeletal osteosarcoma in a young, fit patient?

AIM or doxorubicin/cisplatin? Would you recommend adding methotrexate?

1 Answer available

Outside of a clinical trial, what is your treatment of choice for metastatic melanoma of soft parts or clear cell sarcoma?

Would your treatment approach be similar for a patient with suboptimal performance status?

1 Answer available

What is the utility of immunotherapy in management of malignant peripheral nerve sheath tumors?

In particular, is there any data on the efficacy of Ipilimumab/Nivolumab?

1 Answer available

Do you routinely perform next-generation sequencing on otherwise "low-risk" GIST to guide adjuvant therapy?

Given that risk definitions are based on size, mitotic activity, location and not necessarily genetics/biology, would an otherwise low-risk GIST, who ...

1 Answer available

Would you offer adjuvant chemotherapy to a young adult with undifferentiated embryonal sarcoma of the liver?

What factors make you more likely to offer or omit chemotherapy?

1 Answer available

What is the optimal systemic therapy for dedifferentiated chondrosarcoma?

What is the role for adjuvant versus neoadjuvant chemotherapy?

1 Answer available

How would you approach therapy for a patient with high-grade sarcoma who is unable to tolerate systemic cytotoxic chemotherapy, but whose tumor revealed NRAS G12A, BRCA1, and MET amplification?

Patient with hepC and advanced cirrhosis with multiple liver mets, but may be able to tolerate oral TKI or PARP. Would you offer this or focus on hosp...

1 Answer available

Would you offer neoadjuvant chemotherapy for a large, but recurrent grade 1-2 myxoid chondrosarcoma of knee which is no longer amenable to limb salvage?

Performance status is excellent. Second surgical opinion has also confirmed need for amputation, as the recurrence is now breaching intra and extra ar...

2 Answers available

In a patient who experienced less than 90% necrosis after neoadjuvant chemotherapy for localized, high-grade osteosarcoma, do you recommend adjuvant ifosfamide?

Osteosarcoma conventional type of the distal right femur. cT1N0M0 G3 Stage IIA on MAP protocol completed NACT followed by surgery on radical resection...

1 Answer available

How would you manage a patient with isolated metastatic high grade sarcoma to inguinal and external nodes in a patient with BRCA+ mutation?

This patient had resection of the primary, requiring multiple resections to obtain an R0 resection, followed by adjuvant radiation to the primary. The...

1 Answer available

Which adjuvant treatment(s) would you recommend for an incompletely resected, high grade osteoblastic osteosarcoma of the jaw?

Is chemoradiation a viable strategy in osteosarcoma?

4 Answers available

How do you approach contraception and pregnancy counseling in women of childbearing age with Desmoid tumors who may be contemplating future pregnancy?

Since desmoid tumors are associated with high estrogen states, is there an optimal contraception approach? Is there an optimal time for pregnancy? How...

1 Answer available

For cases of foraminal and extraforaminal monophasic synovial sarcoma post excision with note of residual tumor, would your approach be a second look surgery with re-excision or delivery of adjuvant RT with boost to residual disease?

Would you consider doing a pre-op RT prior to possible re-excision? If yes, what dose would you give? If the location is between L4-L5 spine.

2 Answers available

At what lower end of recurrence risk do you offer adjuvant imatinib for patients with resected GIST?

What is your preferred risk stratification model? There does not appear to be a consensus among experts as to what cutoff in recurrence risk ju...

1 Answer available

What is your preferred first line systemic therapy for metastatic chordoma?

Mets to spine and s/p RT

1 Answer available

How would you treat a patient with recurrent malignant perivascular epithelioid cell neoplasm (PEComa) arising from the kidney and metastatic to lungs?

1 Answer available

How do you modify therapy for patients with severe intolerance to imatinib in the adjuvant setting for GIST?

Do you switch to alternative TKI? Dose reduce?

1 Answer available

Is there a role for adjuvant systemic therapy (in addition to adjuvant radiation) in an early-stage, resected cutaneous angiosarcoma of the head/neck?

Post-auricular cutaneous angiosarcoma, pT1 (19 mm) with negative margins. Unclear if there is any indication for systemic therapy, given early stage a...

1 Answer available

Would you offer immunotherapy for recurrent metastatic Ewing sarcoma if the tumor is MSI high or has high TMB?

2 Answers available

What is the best treatment approach for fit, young patients with extraskeletal Ewing Sarcoma in the lung?

Assuming no access to clinical trial

1 Answer available

How do you approach adjuvant therapy for a resected gastric GIST when the risk for recurrence is discordant between various prediction tools?

For example, gastric GIST, < 5 mitoses/hpf and size > 5 cm but < 10 cm is intermediate by NIH criteria but low by NCCN/CAP criteria. Th...

1 Answer available

What is your typical approach for soft tissue sarcomas of the buttock?

If post-op with clear margins would you prefer adjuvant RT or close observation with surgery for optimal reduction of local recurrence? This particula...

1 Answer available

Would you offer adjuvant chemotherapy for patient with a large, high-grade leiomyosarcoma of the colon who underwent an R0 resection with no lymph node involvement?

> 7cm, grade 3. If chemotherapy offered, what is your preferred adjuvant therapy?

1 Answer available

What adjuvant therapy, if any, would you offer for a high-grade perivascular epithelioid cell (PEComa) tumor of the endometrium after R0 resection?

>10 cm, no metastatic disease identified on staging scans

1 Answer available

What is the optimal neoadjuvant systemic therapy dosing and schedule in a patient with undifferentiated pleomorphic sarcoma of the extremity for whom up-front surgery would portend significant morbidity?

How do you sequence systemic therapy with radiation and surgery? For e.g. how many cycles of ifos/doxorubicin do you administer in this context?

1 Answer available

What is your approach to adjuvant systemic therapy for radiation-induced epithelioid angiosarcoma of the chest wall after successful margin-negative resection?

Nearly 11 cm in size

1 Answer available

How would you approach therapy for a SMARCA4-deficient undifferentiated sarcoma with isolated involvement of a mediastinal lymph node?

No primary thoracic mass identified. Knowing these often following an aggressive clinical course, would you consider concurrent chemo/RT, incorporate ...

1 Answer available

What is the maximum cumulative anthracycline dose you would administer in a patient with metastatic soft tissue sarcoma who is asymptomatic with good disease control?

2 Answers available

How would you manage a recurrent uterine leiomyosarcoma, now status post secondary cytoreduction, with no gross residual disease?

Would you consider adjuvant chemotherapy, radiation therapy, hormone therapy, or surveillance?

1 Answer available

Do you routinely offer chemotherapy after resection of solitary or oligometastatic pulmonary nodule/s in young patients with previously treated soft tissue sarcoma who are otherwise without any evidence of disease?

How does histology, time to distant Mets affect your decision?

1 Answer available

Do you have a preferred systemic therapy for unresectable epithelioid hemangioendothelioma?

In patients with symptomatic disease that observation would not be appropriate, what is your preferred treatment?

1 Answer available

How would you approach therapy for a solitary fibrous tumor of the orbit with residual disease (10%) after surgery?

Which Radiation modality, if any, would be preferred? Typical chemotherapy does not work for SFT. In which circumstance would you use VEGF ( Temozolo...

1 Answer available

How would you approach therapy in a young adult with synovial sarcoma of the head and neck who is not amenable to surgery due to location on the face?

2 Answers available

What systemic therapy would you recommend for metastatic pleomorphic dermal sarcoma with a large inoperable solitary lung metastasis that is too large for radiotherapy?

Potentially, if metastasis responds, could be treated with surgery or radiotherapy

2 Answers available

How would you approach therapy for a young, fit patient with alveolar rhabdomyosarcoma involving the anterior nasal vault/sinuses in the absence of available clinical trials?

Presented with mass projecting into right/left anterior ethmoid complex

1 Answer available

Would you offer adjuvant therapy following successful resection of a solitary lung recurrence of leiomyosarcoma if no other evidence of recurrent disease on PET CT?

1 Answer available

Would you offer adjuvant avapritinib or imatinib for a high-risk, PDGFR D842V-mutated GIST after resection?

Data suggest patients with D842V-mutated or KIT/PDGFRA WT GIST do not respond to imatinib, but NCCN guidelines does not take into consideration mutati...

1 Answer available

Would you offer adjuvant chemotherapy for a large, high-grade radiation-induced malignant peripheral nerve sheath tumor following R1 resection?

>5cm. If so, what is your preferred regimen?

3 Answers available

Would you consider neoadjuvant ifosfamide-based chemotherapy for a large (>10cm) high grade soft tissue extremity sarcoma in an attempt to achieve limb sparing surgery in an otherwise healthy young patient?

Pleomorphic sarcoma

1 Answer available

How would you approach therapy for an elderly patient with NF1-associated metastatic MPNST who remains asymptomatic?

Any strong considerations for infusional vs. bolus doxorubicin?

1 Answer available

What is your approach to unresectable metastatic rhabdomyosarcoma transformed from an embryonal cell germ cell tumor?

Should treatment be based on current histology (rhabdomyosarcoma) or origin (germ cell)?

1 Answer available

What is your approach to systemic treatment of a rapidly progressing, symptomatic, unresectable MPNST arising from Plexiform Neurofibroma in a patient with NF1?

Would you consider using recently approved agent for symptomatic / unresectable PN, Selumetinib prior to Systemic Chemotherapy in this setting?

1 Answer available

What chemotherapy would you recommend for a patient with Ewing Sarcoma who has relapsed after being initially treated with vincristine/doxorubicin/ifosfamide?

2 Answers available

How are you modifying your current sarcoma-directed therapy in the setting of the COVID-19 pandemic?

For example, would you consider switching to an outpatient regimen in lieu of AIM for metastatic soft tissue sarcoma?

1 Answer available

What is your preferred next line of therapy for a fit patient with unresectable, refractory osteosarcoma who has progressed after MAP, local radiation, and IE?

Would you consider regorafenib based on the REGOBONE trial? Or would you consider other agents knowing that we do not have positive survival data with...

3 Answers available

What therapy would you recommend for metastatic myxoid liposarcoma in a young patient with anthracycline cardiomyopathy with EF 25% who failed eribulin?

Would you even consider trabectedin in this case given its cardiotoxicity?

2 Answers available

What is your preferred treatment for a resected composite hemangioendothelioma of the skin arising from a childhood hemangioma?

Tumor 13 cm on back with retiform and kaposiform features; all margins negative except one abuts inked margin; atypical cells with 4 mitosis/HPF. Add...

1 Answer available

How do you treat recurrent dedifferentiated liposarcoma after initial complete resection if the recurrence is multifocal but surgically resectable?

Do you proceed to resection or palliative chemotherapy?

1 Answer available

What is your preferred initial treatment for metastastic primary lung liposarcoma in a fit patient?

How do you choose between single-agent or combination chemotherapy versus newer treatment strategies such as palbociclib?

2 Answers available

How do you approach treatment for solitary fibrous tumor with a multifocal pleural-based metastatic recurrence that is surgically inoperable in a patient with good performance status?

How, if any, do you utilize genomic testing to guide systemic therapy?

2 Answers available

How do you approach pathologic review and genomic testing, if indicated, of a spindle cell neoplasm?

For example, if a biopsy reads: lesion comprised of spindle cells arranged in a fascicular pattern, elongated, hyperchromatic nuclei, focally positive...

1 Answer available

Outside of a clinical trial, how do you approach upfront therapy for a PDGFRA D842V-mutant GIST?

Would your recommendations change in the neoadjuvant versus adjuvant or metastatic setting?

2 Answers available

How do you approach G-CSF use when offering neoadjuvant chemoRT for lower extremity soft-tissue sarcoma?

i.e. doxorubicin, ifosfamide + RT. Do you worry about decreased locoregional control or increased toxicities with the use of G-CSF in combination with...

1 Answer available

How do you treat unresectable localized desmoid tumor?

1 Answer available

How do you counsel patients with localized Ewing's sarcoma who wish to stop or cannot complete the full course of 14 cycles of perioperative chemotherapy?

1 Answer available

How do you approach non-surgical patients with GIST who are intolerant to imatinib 400 mg daily and unlikely to tolerate other TKIs?

Do you reduce the dose to <400 mg daily or employ dosing schedules?

2 Answers available

What is your preferred neoadjuvant chemotherapy course for healthy adult patients with osteosarcoma?

Is there an age limit you use to consider MAP? Would you consider using AIM instead?

3 Answers available

How do you choose your next line of therapy for stage 4 GIST after progression on imatinib?

How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?

2 Answers available

How do you treat GIST with de-differentiation to pleomorphic sarcoma on chronic therapy with imatinib?

How do you treat if adriamycin is not an option?

1 Answer available

Are there any types of sarcomas that you use induction and/or concurrent chemotherapy with radiation prior to surgery?

Specifically concurrent ifosfamide? Induction AIM?

2 Answers available

What is your preferred systemic therapy for metastatic malignant peripheral nerve sheath tumor with early relapse after adjuvant AIM?

Given metastatic disease and not a trial candidate, how would you approach this scenario? How does an underlying diagnosis of NF1 affect your decision...

1 Answer available

For patients who received neoadjuvant Imatinib for initially unresectable GIST tumours, do you routinely prescribe adjuvant therapy or rely on preoperative staging and preoperative mitotic index?

NCCN suggests to consider continuation of imatinib from some single/multi institution non-randomized trials for ~2 years, but does not suggest what fa...

2 Answers available

Is there a preferred neoadjuvant chemotherapy regimen for a marginally-resectable, dedifferentiated, MDM2+ liposarcoma?

2 Answers available

How would you treat someone with unknown primary metastatic SMARCA4 deficient tumor (high-grade tumor with rhabdoid morphology)?

2 Answers available

What is a preferred regimen for metastatic leiomyosarcoma after failure of doxorubicin/olaratumab and gemcitabine/docetaxel?

No actionable mutations were identified on next generation genomic sequencing.

1 Answer available

Would mild hemophilia A that does not require frequent factor replacement be an absolute contraindication to anti-VEGF medications when indicated?

How would you treat metastatic, unresectable, solitary fibrous tumor in a patient with mild hemophilia A? Each anti-VEGF medication comes with a warni...

1 Answer available

What adjuvant therapy, if any, do you consider for high grade extraskeletal osteosarcomas after R0 resection?

Do you use chemotherapy or radiation?

1 Answer available

How do you treat metastatic mesenchymal chondrosarcoma?

How does grade or performance status affect your treatment decisions?

1 Answer available

How would you approach adjuvant chemotherapy for high grade pleomorphic/dedifferentiated liposarcoma?

Does anatomic location (eg retroperitoneal or thoracic) affect your treatment decision?

3 Answers available

Do you recommend stopping olaratumab in patients receiving doxorubicin/olaratumab for treatment of advanced sarcoma?

Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combin...

1 Answer available

When do you give exogenous albumin in an attempt to reduce risk of ifosfamide induced encephalopathy?

1 Answer available

What alternative adjuvant therapy do you recommend to an imatinib intolerant patient with high-risk GIST?

I have seen favorable clinical trial reports on dasatinib for metastatic disease, but no data on possible adjuvant use. NCCN guidelines suggest ...

1 Answer available

How do you approach need for adjuvant therapy after R0 resection of breast angiosarcoma?

What other pathologic features may you use to guide therapy decisions (eg mitoses/grade or NGS)? If you decide on adjuvant therapy, what regimen...

1 Answer available

What is the standard of care (if any) for pediatric desmoplastic round cell tumor?

Is there a role for immunotherapy outside of trial setting?

1 Answer available

Would you offer imatinib to a patient with a high risk GIST (> 10 cm, low Ki-67, s/p complete resection) who initially declined adjuvant therapy, but is now interested 14 months post surgery?

Is there any data to suggest delayed initiation of adjuvant treatment would be beneficial? Or would close surveillance be reasonable? Patient is asymp...

1 Answer available

How would you treat metastatic malignant peripheral nerve sheath tumor in a patient who received adjuvant Adriamycin ( 240 mg/m2) 10 years ago for breast cancer?

Patient currently has bone and lung metastasis.

1 Answer available

Which systemic therapy would you use to treat a poorly-differentiated round cell sarcoma with CIC-DUX4 gene fusion?

CIC-DUX4 fusion sarcoma is a rare entity, the aggressiveness of which is comparable to Ewing's sarcoma. A major dilemma is whether to treat these pati...

1 Answer available

What is your treatment approach to patients with extremity sarcoma with multiple positive regional nodes?

Do you offer neoadjuvant RT with resection and node dissection vs. definitive radiation? How extensive does the nodal disease have to be for you...

2 Answers available

How do you treat a locally-invasive, keratin-positive gastrointestinal spindle-cell neoplasm?

Tumor involves stomach, liver, and lymph nodes. Pathology is suspicious for sarcomatoid carcinoma, possibly sarcomatoid cholangiocarcinoma.

1 Answer available

What treatment options would you consider for a patient with an ECOG PS of 0 with metastatic non-uterine leiomyosarcoma who has progressed on all standard systemic therapies including anthracycline, gemcitabine, taxane, vinorelbine, pazopanib, temozolomide, and trabectidin?

Are there clinic trials that look promising for patients with leiomyosarcoma?

2 Answers available

Should all GISTs be sequenced?

1 Answer available

Papers discussed in this category

Cancer, 2021 Oct 13

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.

JAMA Oncol,

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

Clin. Cancer Res.,

Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival.

The Lancet. Oncology, 2009-11

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.

Ann. Surg. Oncol., 2015 Feb 05

Validation of the MSKCC Gastrointestinal Stromal Tumor Nomogram and Comparison with Other Prognostication Systems: Single-Institution Experience with 289 Patients.

Oral Oncol., 2013 Nov 15

Osteosarcomas of the jaws differ from their peripheral counterparts and require a distinct treatment approach. Experiences from the DOESAK Registry.

Cancer, 2009-07-15

Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment.

Cancer, 2011-10-01

Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma.

Hematol Oncol Clin North Am, 2019 Oct 28

Bone Sarcomas and Desmoids.

Int. J. Radiat. Oncol. Biol. Phys.,

An analysis of 78 breast sarcoma patients without distant metastases at presentation.

Cancer,

Mammary angiosarcoma. The prognostic significance of tumor differentiation.

Eur. J. Cancer,

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-04-15

Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.

Cancer,

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.

Cancer medicine, 2019-01

Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.

Tumori,

EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.

Thromb. Haemost.,

Safety of bevacizumab in mild haemophilia B.

Cancer, 2010-10-01

Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.

European journal of cancer (Oxford, England : 1990), 2013-03

Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.

American journal of clinical oncology, 2019-01

Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.

World J. Gastroenterol.,

Recurrent abdominal liposarcoma: analysis of 19 cases and prognostic factors.

Ann Surg Oncol, 2014 Aug

Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2018-05-23

Neoadjuvant Chemotherapy, Concurrent Chemoradiation, and Adjuvant Chemotherapy for High-Risk Extremity Soft Tissue Sarcoma.

Acta Oncol, 2017 Apr 21

Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.

Lancet Oncol., 2017 Sep 04

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Lancet Oncol., 2012 Sep 04

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

European journal of cancer (Oxford, England : 1990), 2012-06

Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.

The New England journal of medicine, 2018-12-20

Sorafenib for Advanced and Refractory Desmoid Tumors.

Ann. Oncol., 2012 Feb 13

Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions.

Cancer, 2011-11-01

Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.

Case reports in oncology, 2017

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura.

BMC Cancer, 2015 Oct 15

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997-06

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.

British journal of haematology, 2017-08

Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.

Lancet Oncol., 2018 Nov 23

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Ann. Oncol., 2011 Apr 28

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

Lancet Oncol., 2020 Feb 17

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.

Sarcoma, 2020 Jan 30

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).

Translational gastroenterology and hepatology, 2017

The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly?

Surg Oncol, 2016 May 10

Prognosis and management of adult wild type gastrointestinal stromal tumours (GISTs): A pooled analysis and review of literature.

Journal of cutaneous pathology, 2014-11

Expression of the p40 isoform of p63 has high specificity for cutaneous sarcomatoid squamous cell carcinoma.

Lancet Oncol., 2017 May 09

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

J Thorac Oncol, 2019 Nov 18

SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.

ESMO Open,

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998-01

Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.

Annals of surgery, 1982-09

The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-11-20

Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.

Oncologist, 2020 Dec 01

Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma.

The Lancet. Oncology, 2018-03

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

The Lancet. Oncology, 2019-06

Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.

J Hematol Oncol, 2016 Jun 03

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma.

The Lancet. Oncology, 2017-11

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2014-12

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

J Clin Oncol, 2012 Feb 13

Phase II study of imatinib in advanced chordoma.

Ann Oncol, 2013 Apr 04

Phase II study on lapatinib in advanced EGFR-positive chordoma.

Cancer, 2018 Sep 14

Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study.

Annals of surgery, 2014-05

Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk.

Oncologist, 2018 Dec 12

Functional Loss Defines a Targetable Subset in Leiomyosarcoma.

Clin Sarcoma Res, 2013 Dec 18

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.

Int J Radiat Oncol Biol Phys, 2020 Apr 11

Postoperative Radiation Therapy in Patients with Extracranial Chondrosarcoma: A Joint Study of the French Sarcoma Group and Rare Cancer Network.

The American journal of surgical pathology, 2008-01

Sporadic cutaneous angiosarcomas: a proposal for risk stratification based on 69 cases.

Int J Part Ther, 2021 Jun 25

Intensity-Modulated Proton Therapy (IMPT) Treatment of Angiosarcoma of the Face and Scalp.

Annals of surgery, 2004-10

The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.

Pediatric blood & cancer, 2018-02

Consensus and controversies regarding the treatment of rhabdomyosarcoma.

J Surg Oncol, 1981

Sarcomas of the breast: homogenous or heterogenous?

Clin Case Rep, 2021 Nov 16

Primary breast osteosarcoma: A case report and review of the literature.

Clin Case Rep, 2015 Nov 23

Primary osteosarcoma of the breast: a case report.

The American journal of cardiology, 2018-12-01

Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.

Curr Oncol, 2021 Oct 13

Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors.

Cardiooncology, 2019 Jan 29

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.

International journal of radiation oncology, biology, physics, 2005-11-15

Radiation-induced osteosarcomas in the pediatric population.

J Adolesc Young Adult Oncol, 2019 Nov 08

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.

Eur J Cancer, 2017 Nov 28

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.

European journal of cancer (Oxford, England : 1990), 2007 Jan 30

SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.

JAMA oncology, 2018 Jan 01

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

Clin Cancer Res, 2021 Mar 25

Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2021 Feb 25

Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2021 May 14

Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection.

European journal of cancer (Oxford, England : 1990), 2011 Jun 22

Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-12

Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.

The Lancet. Oncology, 2022 Mar 10

PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.

The Lancet. Oncology, 2014 Mar 05

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

European journal of cancer (Oxford, England : 1990), 2019 Jan 25

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.

Current treatment options in oncology, 2023 Apr 05

Osteogenic Sarcoma of the Head and Neck: Is Chemotherapy Needed?

JAMA Oncol, 2020 Feb 20

Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.

Acta oncologica (Stockholm, Sweden), 2021 Sep 23

A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma.

Journal of surgical oncology, 2014-08

Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas.

Medical Oncology

Sarcoma

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology